Interview Preparation for Regulatory Affairs Role IPR Question & Answers

Interview Preparation for Regulatory Affairs Role IPR

Interview Preparation for Regulatory Affairs Role: In the Pharmaceutical industry, Regulatory Affairs is a profession, acting as the interface between the pharmaceutical industry and Drug Regulatory authorities across the world. It is mainly involved in the registration of the drug products prior to their marketing for respective countries. The goals of Regulatory Affairs Professionals are Protection of human health, Ensuring safety, efficacy and quality of drugs with appropriateness and accuracy of product information

Depending on the type of regulatory affairs role you are going for, you are to answer different questions. Therefore the first recommendation for the preparation is to take a look at the job description and try to practice the probable questions. Also, match your CV against the job profile such as the criteria of where and where have you demonstrated the skills, characteristics and experience the interviewer is looking for…

Let’s find out the Roles of Regulatory Affairs professionals

  1. Act as a liaison with regulatory agencies. For translating regulatory requirements into practical workable plans they provide expertise and regulatory intelligence
  2. Organize and prepare scientifically valid NDA, ANDA, INDA, MAA, DMF submissions
  • Adherence and compliance with all the applicable cGMP, ICH, GCP, GLP guidelines, regulations and laws
  1. Adviser to the companies on regulatory aspects and climate that would affect their proposed activities

There are various other roles which Regulatory Affairs professionals play so you must be well aware of what preparation is apt to you.

Interview Preparation for Regulatory Affairs Role IPR

Generally, the main questions during an interview include the following:

  • The interview will go around regulatory authorities or agencies if you have dealt with any.
  • Electronic submissions have evolved as a big part of regulatory affairs work nowadays. You can expect questions on it and your experience to date.
  • If the regulatory affairs job offers to work for a UK affiliate, be prepared to be asked about your experience of dealing with MRHA.
  • Often, in the interview of regulatory affairs job, you will be given the companies that tend to operate on a global level, who are doing global submissions. Since experience matters, in most cases, you can prepare yourself to answer questions about your experience of team working on a global level. It’s better to collect data about the times when you have worked as part of a team on a global level, and the impact you made.

Interview Preparation for Regulatory Affairs Role IPR

Here are some Interview questions and answers:

  1. What is an Investigational New Drug (IND) application?

Ans- It is an application which is filled with FDA to get approval for legally testing an experimental drug on human subjects in the USA.

  1. What is CTD?

Ans-The Common Technical Document (CTD) is a set of specification for application dossier, for the registration of Medicines and designed to be used across Europe, Japan and the United States.Quality, Safety and Efficacy information is assembled in a common format through CTD .The CTD is maintained by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). CTD format for submission of drug registration applications/dossiers is widely accepted by regulatory authorities of other countries too like Canada, Australia etc.

  1. 3. What are the modules in CTD?

Ans- The Common Technical Document is divided into five modules:

Module 1. Administrative information and prescribing information

Module 2. Common Technical Document summaries (Overview and summary of modules 3 to 5)

Module 3. Quality

Module 4. Nonclinical Study Reports (toxicology studies)

Module 5. Clinical Study Reports (clinical studies)

  1. 4. What are the chemical classification codes for NDA?

Ans-

Number Meaning
1 New molecular entity (NME)
2 New ester, new salt, or other noncovalent derivative
3 New formulation
4 New combination
5 New manufacturer
6 New indication
7 Drug already marketed, but without an approved NDA
8 OTC (over-the-counter) switch
  1. What is a New Drug Application?

Ans- The NDA is the vehicle through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.  The data gathered during the animal studies and human clinical trials of an Investigational new drug become part of the NDA

In simple words, “It is an application which is filed with FDA to market a new Pharmaceutical for sale in USA”

  1. What is an Abbreviated New Drug Application (ANDA)?

Ans- It is an application filed with FDA, for a U.S. generic drug approval for an existing licensed medication or approved drug.

In simple words, “It is an application for the approval of Generic Drugs “

  1. What is a Generic Drug Product?

Ans- A generic drug product is the one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.

  1. What is a DMF?

Ans- A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.

Important facts regarding DMFs

  • It is submitted to FDA to provide confidential information
  • Its submission is not required by law or regulations
  • It is neither approved nor disapproved
  • It is filed with FDA to support NDA, IND, ANDA another DMF or amendments and supplements to any of these
  • It is provided for in the 21 CFR (Code of Federal Regulations) 314. 420
  • It is not required when applicant references its own information
  1. What are the types of DMF’s?

Ans-

Type I: Manufacturing Site, Facilities, Operating Procedures, and Personnel (No longer accepted by FDA)

Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation, or Drug Product

Type III: Packaging Material

Type IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their Preparation

Type V: FDA Accepted Reference Information (FDA discourages its use)

  1. What is a 505 (b)(2) application ?

Ans- 505 (b)(2) application is a type of NDA for which one or more investigations relied on by applicant for approval were not conducted by/for applicant and for which applicant has not obtained a right of reference.

  1. What kind of application can be submitted as a 505(b)(2) application?

Ans-

  • New chemical entity (NCE)/new molecular entity (NME)
  • Changes to previously approved drugs
  1. What are the examples of changes to approved drug products for which 505(b)(2) application should be submitted ?

Ans-

  • Change in dosage form.
  • Change in strength
  • Change in route of administration
  • Substitution of an active ingredient in a formulation product
  • Change in formulation
  • Change in dosing regimen
  • Change in active ingredient
  •  New combination Product
  • New indication
  • Change from prescription indication to OTC indication
  • Naturally derived or recombinant active ingredient
  • Bioinequivalence
  1. What is Hatch-Waxman act?

Ans-It is the popular name for Drug Price Competition and Patent Term Restoration Act, 1984. It is considered as the landmark legislation which established the modern system of generic drugs in USA. Hatch-Waxman amendment of the federal food, drug and cosmetics act established the process by which, would be marketers of generic drugs can file Abbreviated New Drug Application (ANDA) to seek FDA approval of generic drugs. Paragraph IV of the act, allows 180 day exclusivity to companies that are the “first-to-file” an ANDA against holders of patents for branded counterparts.

In simple words “Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics”

  1. What are the patent certifications under Hatch-Waxman act?

Ans-As per the Hatch and Waxman act, generic drug and 505 (b) (2) applicants should include certifications in their applications for each patent listed in the “Orange Book” for the innovator drug. This certification must state one of the following:

(I) that the required patent information relating to such patent has not been filed (Para I certification);

(II) that such patent has expired (Para II certification);

(III) that the patent will expire on a particular date (Para III certification); or

(IV) that such patent is invalid or will not be infringed by the drug, for which approval is being sought(Para IV certification).

A certification under paragraph I or II permits the ANDA to be approved immediately, if it is otherwise eligible. A certification under paragraph III indicates that the ANDA may be approved when the patent expires.

  1. What is meant by 180 day exclusivity?

Ans-The Hatch-Waxman Amendments provide an incentive of 180 days of market exclusivity to the “first” generic applicant who challenges a listed patent by filing a paragraph IV certification and thereby runs the risk of having to defend a patent infringement suit.

180 Day Exclusivity could be granted to more than one applicant. The recent example is- 180 day exclusivity was granted to Ranbaxy and Watson Laboratories for marketing generic version of Lipitor ( Atorvastatin calcium).

Interview Preparation for Regulatory Affairs Role IPR Question and Answers

  1. What are the procedures for Approval of Drug in EU?

Centralised Procedure (CP)

Decentralised Procedure (DCP)

Mutual Recognition Procedure (MRP)

National Procedure (NP)

  1. What is the Full form of abbreviation, CEP?

Certificate of Suitability to the monographs of the European Pharmacopoeia (or) Certificate of suitability of monographs of the European Pharmacopoeia (or) Certification of suitability of European Pharmacopoeia monographs

It is also informally referred to as Certificate of Suitability (COS)

  1. What is a CEP?

It is the certificate which is issued by Certification of Substances Division of European Directorate for the Quality of Medicines (EDQM), when the manufacturer of a substance provides proof that the quality of the substance is suitably controlled by the relevant monographs of the European Pharmacopoeia.

  1. What is ICH?

Ans-International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH): is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of pharmaceutical product registration.

  1. What is a Marketing Authorization Application?

Ans- It is an application filed with the relevant authority in the Europe (typically, the UK’s MHRA or the EMA’s Committee for Medicinal Products for Human Use (CHMP)) to market a drug or medicine.

As per UK’s MHRA-

Applications for new active substances are described as ‘full applications’.

Applications for medicines containing existing active substances are described as ‘abbreviated’ or ‘abridged applications’.